In November 2017, AmerisourceBergen reached an “agreement in principle” with the United States Attorney’s Office for the Eastern District of New York to resolve civil claims under the False Claims Act involving the distribution of oncology support drugs from a facility not registered with the U.S. Food and Drug Administration. AmerisourceBergen agreed to pay $625 million to settle the matter. In August 2017, AmerisourceBergen pleaded guilty to a misdemeanor offense and paid $260 million in connection with the failure of AmerisourceBergen subsidiary Medical Initiatives to duly register with the FDA (see AmerisourceBergen instance, “Medical Initiatives Syringe Program – Criminal Settlement”). The settlement was finalized in October 2018.